GDAC Statement on Takeda’s Announcement about their Dengue Vaccine Phase 3 Efficacy Trial

SEOUL, REPUBLIC OF KOREA – JANUARY 30, 2019— Yesterday, Takeda Pharmaceutical Company Limited announced their live-attenuated tetravalent dengue vaccine candidate, designated as TAK-003, had met the primary ...

2018 GDAC Symposium- “Present and Future Dengue Vaccines”

On November 1-2, 2018,  the Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC) convened a 1.5 day consultative meeting on “Present and Future of Dengue Vaccines” in New Orleans, Louisiana, USA. The ...

Webinar hosted by GDAC- Dengue vaccination: Where do we go from here?

On September 7th, 2018, the WHO published its new position on the dengue vaccine, Dengvaxia®. The WHO guidance was updated to account for new long-term clinical data on the vaccine that led Sanofi Pasteur to recommend ...